Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases
on behalf of the REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases'. Together they form a unique fingerprint.